Table 2.
Demographic characteristics of recipients by treatment group
| Characteristic | Basiliximab + belatacept HD + MMF | Belatacept HD + MMF | Belatacept LD + MMF | Tac + MMF | Tac |
|---|---|---|---|---|---|
| (n = 50) | (n = 48) | (n = 49) | (n = 53) | (n = 50) | |
| Mean age, years | 54.0 | 53.4 | 55.2 | 53.0 | 54.7 |
| Sex, male, % | 78 | 71 | 63 | 87 | 84 |
| Race, % | |||||
| White | 88 | 83 | 94 | 93 | 86 |
| Black | 8 | 6 | 2 | 6 | 4 |
| Cause of ESLD, % | |||||
| Noncholestatic cirrhosis | 76 | 69 | 67 | 74 | 82 |
| HCV-positive, % | 46 | 48 | 43 | 47 | 48 |
| Mean MELD score | 22.6 | 21.1 | 20.6 | 24.3 | 21.6 |
| Hepatorenal syndrome, % | 10 | 10 | 10 | 13 | 6 |
ESLD, end-stage liver disease; HCV, hepatitis C virus; HD, high dose, LD, low dose; MELD, Model for End-Stage Liver Disease; MMF, mycophenolate mofetil; Tac, tacrolimus.